A carregar...
Optimizing Oncolytic Viral Design to Enhance Antitumor Efficacy: Progress and Challenges
The field of oncolytic virotherapy has seen remarkable advancements in last two decades, leading to approval of the first oncolytic immuno-virotherapy, Talimogene Laherparepvec, for the treatment of melanoma. A plethora of preclinical and clinical studies have demonstrated excellent safety profiles...
Na minha lista:
| Publicado no: | Cancers (Basel) |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
MDPI
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7352900/ https://ncbi.nlm.nih.gov/pubmed/32604787 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12061699 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|